Standard

Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. / Nushtaeva, Anna A.; Stepanov, Grigory A.; Semenov, Dmitry V. и др.

в: BMC Cancer, Том 18, № 1, 728, 09.07.2018, стр. 728.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Nushtaeva, AA, Stepanov, GA, Semenov, DV, Juravlev, ES, Balahonova, EA, Gerasimov, AV, Sidorov, SV, Savelyev, EI, Kuligina, EV, Richter, VA & Koval, OA 2018, 'Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents', BMC Cancer, Том. 18, № 1, 728, стр. 728. https://doi.org/10.1186/s12885-018-4635-8

APA

Nushtaeva, A. A., Stepanov, G. A., Semenov, D. V., Juravlev, E. S., Balahonova, E. A., Gerasimov, A. V., Sidorov, S. V., Savelyev, E. I., Kuligina, E. V., Richter, V. A., & Koval, O. A. (2018). Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. BMC Cancer, 18(1), 728. [728]. https://doi.org/10.1186/s12885-018-4635-8

Vancouver

Nushtaeva AA, Stepanov GA, Semenov DV, Juravlev ES, Balahonova EA, Gerasimov AV и др. Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. BMC Cancer. 2018 июль 9;18(1):728. 728. doi: 10.1186/s12885-018-4635-8

Author

Nushtaeva, Anna A. ; Stepanov, Grigory A. ; Semenov, Dmitry V. и др. / Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. в: BMC Cancer. 2018 ; Том 18, № 1. стр. 728.

BibTeX

@article{909401b37f7048b58e7f5dc15f11d14a,
title = "Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents",
abstract = "Background: The phenomenon of chemotherapy-resistant cancers has necessitated the development of new therapeutics as well as the identification of specific prognostic markers to predict the response to novel drugs. Primary cancer cells provide a model to study the multiplicity of tumourigenic transformation, to investigate alterations of the cellular response to various molecular stimuli, and to test therapeutics for cancer treatment. Methods: Here, we developed primary cultures of human breast tissue - normal cells (BN1), cancer cells (BC5), and cells from a chemotherapy-treated tumour (BrCCh1) to compare their response to conventional chemotherapeutics and to innate immunity stimulators with that of the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. Expression of the progesterone receptor (PGR), oestrogen receptor (ER) α and β, human epidermal growth factor receptor (HER) 2 and 3 and aromatase CYP19, as well as expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) mRNA in human breast cells were characterized. Results: We revealed that BC5 carcinoma cells were PGRlow/ERbhigh/ERa-/Cyp19+, the BrCCh1 cells that originated from the recurrent tumour were PGR-/ERb+/ERa-/Cyp19+, and normal BN cells were PGR-/ERb+/ERa-/Cyp19high. The treatment of primary culture cells with antitumour therapeutics revealed that BrCCh1 cells were doxorubicine-resistant and sensitive to cisplatin. BC5 cells exhibited low sensitivity to tamoxifen and cisplatin. The innate immunity activators interferon-α and an artificial small nucleolar RNA analogue increased expression of IFIT3 at different levels in primary cells and in the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. The relative level of activation of IFIT3 expression was inversely correlated with the baseline level of IFIT3 mRNA expression in breast cell lines. Conclusion: Our data demonstrated that primary cancer cells are a useful model for the development of novel cancer treatments. Our findings suggest that expression of IFIT3 mRNA can be used as a prognostic marker of breast cancer cell sensitivity to immunostimulating therapeutics.",
keywords = "Breast cancer, Cancer stem cells, CD24, CD44, Hormone receptor, IFIT3, Interferon-α, Primary culture, Prognostic marker, SnoRNA, Hyaluronan Receptors/analysis, CD24 Antigen/analysis, Humans, Receptors, Estrogen/analysis, Adjuvants, Immunologic/therapeutic use, Intracellular Signaling Peptides and Proteins/genetics, Cell Line, Tumor, Female, RNA, Messenger/analysis, Breast Neoplasms/chemistry, MOLECULAR SUBTYPES, ACTIVATION, SENSITIVITY, HEPATOCELLULAR-CARCINOMA, Interferon-alpha, ADENOCARCINOMA, QUANTIFICATION, PHENOTYPE, snoRNA, EPITHELIAL-MESENCHYMAL TRANSITION, STEM-CELL, PERSONALIZED-MEDICINE",
author = "Nushtaeva, {Anna A.} and Stepanov, {Grigory A.} and Semenov, {Dmitry V.} and Juravlev, {Evgeny S.} and Balahonova, {Evgenia A.} and Gerasimov, {Alexey V.} and Sidorov, {Sergey V.} and Savelyev, {Eugeniy I.} and Kuligina, {Elena V.} and Richter, {Vladimir A.} and Koval, {Olga A.}",
note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2018",
month = jul,
day = "9",
doi = "10.1186/s12885-018-4635-8",
language = "English",
volume = "18",
pages = "728",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents

AU - Nushtaeva, Anna A.

AU - Stepanov, Grigory A.

AU - Semenov, Dmitry V.

AU - Juravlev, Evgeny S.

AU - Balahonova, Evgenia A.

AU - Gerasimov, Alexey V.

AU - Sidorov, Sergey V.

AU - Savelyev, Eugeniy I.

AU - Kuligina, Elena V.

AU - Richter, Vladimir A.

AU - Koval, Olga A.

N1 - Publisher Copyright: © 2018 The Author(s).

PY - 2018/7/9

Y1 - 2018/7/9

N2 - Background: The phenomenon of chemotherapy-resistant cancers has necessitated the development of new therapeutics as well as the identification of specific prognostic markers to predict the response to novel drugs. Primary cancer cells provide a model to study the multiplicity of tumourigenic transformation, to investigate alterations of the cellular response to various molecular stimuli, and to test therapeutics for cancer treatment. Methods: Here, we developed primary cultures of human breast tissue - normal cells (BN1), cancer cells (BC5), and cells from a chemotherapy-treated tumour (BrCCh1) to compare their response to conventional chemotherapeutics and to innate immunity stimulators with that of the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. Expression of the progesterone receptor (PGR), oestrogen receptor (ER) α and β, human epidermal growth factor receptor (HER) 2 and 3 and aromatase CYP19, as well as expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) mRNA in human breast cells were characterized. Results: We revealed that BC5 carcinoma cells were PGRlow/ERbhigh/ERa-/Cyp19+, the BrCCh1 cells that originated from the recurrent tumour were PGR-/ERb+/ERa-/Cyp19+, and normal BN cells were PGR-/ERb+/ERa-/Cyp19high. The treatment of primary culture cells with antitumour therapeutics revealed that BrCCh1 cells were doxorubicine-resistant and sensitive to cisplatin. BC5 cells exhibited low sensitivity to tamoxifen and cisplatin. The innate immunity activators interferon-α and an artificial small nucleolar RNA analogue increased expression of IFIT3 at different levels in primary cells and in the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. The relative level of activation of IFIT3 expression was inversely correlated with the baseline level of IFIT3 mRNA expression in breast cell lines. Conclusion: Our data demonstrated that primary cancer cells are a useful model for the development of novel cancer treatments. Our findings suggest that expression of IFIT3 mRNA can be used as a prognostic marker of breast cancer cell sensitivity to immunostimulating therapeutics.

AB - Background: The phenomenon of chemotherapy-resistant cancers has necessitated the development of new therapeutics as well as the identification of specific prognostic markers to predict the response to novel drugs. Primary cancer cells provide a model to study the multiplicity of tumourigenic transformation, to investigate alterations of the cellular response to various molecular stimuli, and to test therapeutics for cancer treatment. Methods: Here, we developed primary cultures of human breast tissue - normal cells (BN1), cancer cells (BC5), and cells from a chemotherapy-treated tumour (BrCCh1) to compare their response to conventional chemotherapeutics and to innate immunity stimulators with that of the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. Expression of the progesterone receptor (PGR), oestrogen receptor (ER) α and β, human epidermal growth factor receptor (HER) 2 and 3 and aromatase CYP19, as well as expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) mRNA in human breast cells were characterized. Results: We revealed that BC5 carcinoma cells were PGRlow/ERbhigh/ERa-/Cyp19+, the BrCCh1 cells that originated from the recurrent tumour were PGR-/ERb+/ERa-/Cyp19+, and normal BN cells were PGR-/ERb+/ERa-/Cyp19high. The treatment of primary culture cells with antitumour therapeutics revealed that BrCCh1 cells were doxorubicine-resistant and sensitive to cisplatin. BC5 cells exhibited low sensitivity to tamoxifen and cisplatin. The innate immunity activators interferon-α and an artificial small nucleolar RNA analogue increased expression of IFIT3 at different levels in primary cells and in the immortalized breast cells MCF7, MDA-MB-231, and MCF10A. The relative level of activation of IFIT3 expression was inversely correlated with the baseline level of IFIT3 mRNA expression in breast cell lines. Conclusion: Our data demonstrated that primary cancer cells are a useful model for the development of novel cancer treatments. Our findings suggest that expression of IFIT3 mRNA can be used as a prognostic marker of breast cancer cell sensitivity to immunostimulating therapeutics.

KW - Breast cancer

KW - Cancer stem cells

KW - CD24

KW - CD44

KW - Hormone receptor

KW - IFIT3

KW - Interferon-α

KW - Primary culture

KW - Prognostic marker

KW - SnoRNA

KW - Hyaluronan Receptors/analysis

KW - CD24 Antigen/analysis

KW - Humans

KW - Receptors, Estrogen/analysis

KW - Adjuvants, Immunologic/therapeutic use

KW - Intracellular Signaling Peptides and Proteins/genetics

KW - Cell Line, Tumor

KW - Female

KW - RNA, Messenger/analysis

KW - Breast Neoplasms/chemistry

KW - MOLECULAR SUBTYPES

KW - ACTIVATION

KW - SENSITIVITY

KW - HEPATOCELLULAR-CARCINOMA

KW - Interferon-alpha

KW - ADENOCARCINOMA

KW - QUANTIFICATION

KW - PHENOTYPE

KW - snoRNA

KW - EPITHELIAL-MESENCHYMAL TRANSITION

KW - STEM-CELL

KW - PERSONALIZED-MEDICINE

UR - http://www.scopus.com/inward/record.url?scp=85049793867&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4635-8

DO - 10.1186/s12885-018-4635-8

M3 - Article

C2 - 29986702

AN - SCOPUS:85049793867

VL - 18

SP - 728

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 728

ER -

ID: 17862356